Gobran, M., Alabiad, M., Hafeez, A., Hanafy, S., Salem, A. (2021). Mycosis Fungoides Diagnosis Using TOX Versus Old Panel Immunohistochemical Markers. The Egyptian Journal of Hospital Medicine, 85(2), 4331-4337. doi: 10.21608/ejhm.2021.209428
Mai Ahmed Gobran; Mohamed Ali Alabiad; Abeer Hafeez; Sabah Mohamed Hanafy; Amira Salem. "Mycosis Fungoides Diagnosis Using TOX Versus Old Panel Immunohistochemical Markers". The Egyptian Journal of Hospital Medicine, 85, 2, 2021, 4331-4337. doi: 10.21608/ejhm.2021.209428
Gobran, M., Alabiad, M., Hafeez, A., Hanafy, S., Salem, A. (2021). 'Mycosis Fungoides Diagnosis Using TOX Versus Old Panel Immunohistochemical Markers', The Egyptian Journal of Hospital Medicine, 85(2), pp. 4331-4337. doi: 10.21608/ejhm.2021.209428
Gobran, M., Alabiad, M., Hafeez, A., Hanafy, S., Salem, A. Mycosis Fungoides Diagnosis Using TOX Versus Old Panel Immunohistochemical Markers. The Egyptian Journal of Hospital Medicine, 2021; 85(2): 4331-4337. doi: 10.21608/ejhm.2021.209428
Mycosis Fungoides Diagnosis Using TOX Versus Old Panel Immunohistochemical Markers
Background: For primary cutaneous lymphoma, mycosis fungoides (MF) is the most prevalent form with skin-homing T cells plus clonal proliferation of CD4. In many CTCLs, thymocyte selection associated with the HMG-box (TOX) is an uncontrolled gene, together with MF in comparison with controls. Early mycosis fungoides is difficult to diagnose, and, its distinction from inflammatory diseases is sometimes impossible. Objective: In this study, we compared the TOX vs C7 and CD4 expression as an early mycosis fungoides diagnostic markers & to assess their ability to differentiate Mycosis fungoides from benign cutaneous inflammatory diseases (BCID). Materials and methods: 60 patients who had been previously diagnosed as MF (30 cases) and BCID (30 cases). All were evaluated histopathologically using H & E and immunohistochemically staining for TOX, CD7 & CD 4. Results: There was statistically significant difference between MF and BCID with increased TOX, CD7 & CD4 expression among MF than among BCID and ability of TOX to detect all true positive cases (100.0%) compared to 83.3% for CD4 and 13.3% for CD7. TOX had the highest sensitivity (100.0%) and accuracy (88.3%) followed by CD4 with sensitivity of 88.3% and accuracy of 66.7%, (P < 0.001). Conclusion: TOX had the highest sensitivity (100.0%) & accuracy (88.3%) followed by CD4 with sensitivity of 88.3% and accuracy of 66.7%. Our results suggest that TOX is a useful marker in diagnosis of MF & differentiating it from BCID.